Clinical Trial Update: Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 drug-drug interaction study evaluating ivacaftor (VX-770) and lumacaftor (VX-809) in healthy subjects to support cystic fibrosis therapies. The study ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (VX-770) (ivacaftor)
• Lumacaftor (VX-809) (lumacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED